Robert Steinbrook

Learn More
116 not approved nesiritide and awaits the results of a trial involving 1900 patients before it will even consider doing so. 5 In my view, nesiritide has not yet met the minimal criteria for safety and efficacy. Until a trial definitively proves that this drug reduces the risk of death or repeated hospitalization for heart failure, there will be questions(More)
A series of articles in the New England Journal of Medicine has questioned whether the conflict of interest movement has gone too far in its campaign to stop the drug industry influencing the medical profession. Here, three former senior NEJM editors respond with dismay 1779 A seriously flawed and inflammatory attack on conflict of interest policies and(More)
  • 1